(2): 365 Journal of Antimicrobial Chemotherapy '); //> Pp.ADVANCE ACCESS ORIGINALLY PUBLISHED ONLINE ON DECEMBER 12, 2007 Journal of Antimicrobial Chemotherapy 2008 61(2):365-370; doi:10.This Article All Versions of this Article: 61/2/365 _most recent_ Services Google Scholar PubMed ORIGINAL RESEARCH POTENTIAL SYNERGY ACTIVITY OF THE NOVEL CERAGENIN, CSA-13, AGAINST CLINICAL ISOLATES OF _PSEUDOMONAS AERUGINOSA_, INCLUDING MULTIDRUG-RESISTANT _P_.JUDY N.RONALD N.HELIO S.PAUL B.AND MICHAEL J._ 1 Anti-infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI 48201, USA 2 JMI Laboratories, North Liberty, IA, USA 3 Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602, USA _ _Received 15 August 2007;_ _returned 23 September 2007;_ _revised 23 October 2007;_ _accepted 30 October 2007_ Corresponding author.+1-313-577-4376; Fax: +1-313-577-8915; E-mail: m.Previous data from our research had shown that the novel ceragenin, CSA-13, demonstrated concentration-dependent bactericidal activity against glycopeptide-resistant _Staphylococcus aureus_.It is unknown whether CSA-13 demonstrates a similar property against _Pseudomonas aeruginosa_.Evaluated CSA-13 antipseudomonal activitypared with cefepime, meropenem, piperacillin/tazobactam, tobramycin and ciprofloxacin by susceptibility testing as well as inbination with cefepime, tobramycin and ciprofloxacin.Methods: Fifty clinical isolates of _P_.Were analysed by reference broth microdilution methods.Strains with various susceptibilities were evaluated by time-killing curve (TKC) analysis at 0.2x and 4x MIC using an initial inoculum of 106 cfu/mL.Testing, TKC analysis of CSA-13 alone and inbination with cefepime, tobramycin and ciprofloxacin at 0.Was performed.Results: CSA-13 MIC50 and MBC50 were 16 and 16 mg/L, respectively.Demonstrated concentration-dependent activity, with CSA-13 at 4x MIC achieving earliest kill at 1 h (99.Limit).Analysis demonstrated synergy or additive effect with cefepime and ciprofloxacin, in some cases achieving early synergy.Addition of tobramycin to CSA-13 resulted in no difference in kill for two strains.Conclusions: CSA-13 showed concentration-dependent activity against clinical isolates of _P_.Including multidrug-resistant _P_.The addition of cefepime or ciprofloxacin to CSA-13 enhanced bacterial kill, achieving early synergy.Read more Effects of estradiol and raloxifene on arterial thrombosis in ovariectomized mice.
Get more Chemotherapy and tamoxifen reduce risk of second breast cancer, study finds
